Le Lézard
Classified in: Health, Science and technology
Subject: PDT

UC Irvine Spinout, Debut, Seeks to Transform Chemical Manufacturing Industry


SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Debut Biotechnology, a startup located in San Diego, California, has exclusively licensed two inventions from the University of California, Irvine (UCI) that will allow continuous manufacturing in the pharmaceutical, alcoholic beverage, and cannabinoid industries. Utilizing easy-to-use enzyme cartridges, complex pharmaceuticals will be created using only cells, alcohol will be created in minutes, and cannabinoids will be manufactured without the plant.

Debut Biotechnology Team (Left to Right): Dr. Nicholas Brideau (Senior Scientist), Brady Beauchamp (Co-Founder & COO), Megha Rawal (Research Scientist), Dr. Gregory Weiss (Co-Founder & Advisor), Dr. Joshua Britton (Co-Founder & CEO).

"We believe the way chemicals and pharmaceuticals are created in the next ten years will be performed using enzymes," said Dr. Joshua Britton, founder, Debut Biotechnology. "Enzymes are beautiful machines found in nature that perform complex chemical transformations most chemists can only dream about. We use these machines to construct pharmaceuticals and high value molecules thus allowing us to re-think chemical synthesis." 

The way in which chemicals and pharmaceuticals are made is undergoing a paradigm shift. Reactions are typically done in large containers known as 'batch' reactors. However, continuous manufacturing is changing the way we think about making chemicals. While companies in this area are focused on translating traditional chemistry into continuous manufacturing, Debut sees a different approach and outcome for the future of manufacturing.

"Over the next ten years, chemical manufacturing will look much different than it does today. At Debut, we create products that enable this forthcoming change," Britton said.

Britton's words echo those of former FDA Commissioner Scott Gottlieb who said, "Continuous manufacturing helps to ensure consistently-made products, allows manufacturers to more easily scale their manufacturing operations to meet demand, and can help reduce drug shortages by minimizing operational stops and starts."

Debut biotechnology is housed at BioLabs in San Diego and aims for their products to decrease process costs, time, energy, land usage, and water typically associated with chemical manufacturing. 

"We are excited that Debut is moving this technology from the labs at UCI to realize its transformative potential in continuous manufacturing, thereby benefitting the economy and society at large," noted Casie Kelly, assistant director of Licensing, UCI Beall Applied Innovation.

More information on Debut Biotechnology and their technology can be found at www.debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology, Inc. located in San Diego, Calif., creates advanced manufacturing processes for high value molecules by combining immobilized enzymes with continuous manufacturing across a wide range of industries.

Contact: brady@debutbiotech.com

 

SOURCE Debut Biotechnology


These press releases may also interest you

at 23:15
Of the thousands of firms nationwide considered for the honor, PrideStaff, a national, franchised staffing organization, is pleased to announce that they were ranked No. 40 among the elite group of 250 firms named to Forbes' 2020 List of America's...

at 23:00
ProKNX, the award-winning start-up based in the South of France, has proudly announced the upcoming launch of their newest home automation product that will take the smart home industry by storm. Jens Kastensson, CTO of ProKNX stated that the initial...

at 22:40
Rakuten Mobile, Inc. and NEC Corporation (NEC; TSE: 6701) today announced that the two companies have reached an agreement to jointly develop the containerized standalone (SA) 5G core network (5GC) to be utilized in Rakuten Mobile's fully virtualized...

at 22:15
Mitsubishi Electric Corporation (TOKYO:6503) announced today that it has developed a cooperative artificial intelligence (AI) technology that enhances work collaboration between humans and machines by using inverse reinforcement learning (IRL) to...

at 22:10
MedX Health Corp. ("MedX") announces that pursuant to the agreement for an online marketing and awareness program through AGORACOM, that was announced in the Press Release dated June 1, 2020, it has settled the first payment to AGORACOM, in the...

at 21:56
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the pricing of its initial public offering of 9,000,000 shares of its common...



News published on 18 september 2019 at 20:42 and distributed by: